The economics of improved cancer survival rates: better outcomes, higher costs
Authors:
- Carin A Uyl-De GrootCGCarin A Uyl-De Groot
- Saskia de GrootSGSaskia de Groot
- Adri SteenhoekASAdri Steenhoek
- 1 June 2010
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 10 (3) , 283-292
Abstract
In 2006, over three million new cases of cancer were diagnosed in Europe. This number will increase in the coming years as a result of an aging population and population growth. Advances in the diagnosis and treatment of cancer have resulted in increased survival rates. Simultaneously, increasing costs of screening, diagnosis and the treatment of cancer could threaten the ability to ensure high-quality care and provide access to care for all patients. New genetic tests and biomarkers may help to identify those subtypes of patients that would be most likely to benefit from new cancer drugs. In our opinion, there is still much to gain in cancer diagnosis and treatment but these gains should be worth the costs.Keywords
This publication has 14 references indexed in Scilit:
- How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion QuestionJNCI: Journal of the National Cancer Institute, 2009
- The Influence of Sex in Non-Small Cell Lung CancerOnkologie, 2009
- Financial Consequences of Improved Treatments for Colorectal CancerSeminars in Colon and Rectal Surgery, 2008
- Cancer screening: Evidence and practice in Europe 2008European Journal of Cancer, 2008
- Making progress against cancer in Europe in 2008European Journal of Cancer, 2008
- Imaging and cancer: A reviewMolecular Oncology, 2008
- Estimates of the cancer incidence and mortality in Europe in 2006Annals of Oncology, 2007
- Perspectives on the Cost of Cancer CareJournal of Clinical Oncology, 2007
- Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic reviewThe Lancet, 2003
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001